1Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents [ J ]. Semin Oncol, 1999, 26(2 Suppl 6) :3 - 10. 被引量：1
2Adjei AA. Clinical studies of pemetrexed and gemcitabine combinations [ J]. Ann Oncol, 2006 , ( Suppl 5 ) : v29 - v32. 被引量：1
3Vogelzang N J, Rusthoven JJ, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [ J ]. Clin Oncol,2003,21 (14) :2636 - 2644. 被引量：1
4Manegold C, Gatzemeier U, yon Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA ( LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase Ⅱ trial [J]. Ann Oneol, 2000, 11(4) :435 -440. 被引量：1
5Shepherd FA, Dancey J, Arnold A, et al. Phase Ⅱ study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group [J] . Cancer,2001,92(3) :595 -600. 被引量：1
同被引文献11
1Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents [J] . Semin Oncol, 1999, 26 (2 Suppl 6) : 3-10. 被引量：1
2Smit EF, Mattson K, von Pawel J, et al. ALIMTA (Pemetrexed disodium) as second line treatment of non-small cell lung cancer: a phase lI study [J] . Ann Oncol, 2003, 14 (3) : 455-460. 被引量：1
3Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer [J] . J Clin Oncol, 2006, 24 (27) : 4405-4411. 被引量：1
